phenylalanyl- prolyl- arginine- chloromethyl ketone (PPACK)

do not confuse with Pro-Phe-Arg-CH2-Cl or with Phe-Phe-Arg-CH2-Cl, both sometimes also referred to as PPACK

Also Known As:

PPACK; D-Phe-Pro-Arg-chloromethyl ketone; FPR-cmk; FPRCK; FPRMeCl; Phe-Pro-Arg-CH2-Cl; Phe-Pro-Arg-CK; phenylalanyl-prolyl-arginyl-chloromethane

Networked: 32 relevant articles (4 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Amino Acid Chloromethyl Ketones
    - phenylalanyl-prolyl-arginine-chloromethyl ketone: 32

Experts

1.	Wickline, Samuel A: 6 articles (11/2021 - 11/2013)
2.	Pan, Hua: 4 articles (11/2021 - 11/2013)
3.	Palekar, Rohun U: 4 articles (11/2016 - 11/2013)
4.	Gaut, Joseph P: 3 articles (11/2021 - 04/2015)
5.	Chen, Junjie: 2 articles (01/2018 - 04/2015)
6.	Vemuri, Chandu: 2 articles (11/2016 - 04/2015)
7.	Myerson, Jacob W: 2 articles (03/2016 - 11/2013)
8.	Baldwin, Margaret: 1 article (11/2021)
9.	Chalfant, Charles E: 1 article (11/2021)
10.	Stephenson, Daniel J: 1 article (11/2021)

Related Diseases

1.	Thrombosis (Thrombus) 12/01/1999 - "In PPACK-treated blood, both NC (3.3-fold) and PC (2.7-fold) increased platelet attachment on elevation of the shear rate from 500 to 1640 s(-1), whereas in citrated blood, adhesion and thrombus growth on PC were negligible under the high shear rate, unlike on NC (1.9-fold increase). " 10/01/1994 - "In contrast to the systemic administration of PPACK, local delivery produced maximal inhibition of thrombosis without alterations in hemostasis." 06/01/1994 - "The inhibition of thrombosis associated with intravenous PPACK was dose related. " 11/01/2016 - "The static model of stent thrombosis used in this study indicated a significant reduction in thrombus deposition with PPACK-NP treatment (0.00067 ± 0.00026 g; n = 3) compared with control NP (0.0098 ± 0.0015 g; n = 3; P = .026) in PPP. " 11/01/2016 - "Additionally, an in vitro model of stent thrombosis under flow conditions established that PPACK-NP treatment inhibited thrombus deposition on stents significantly. "
2.	Necrosis 11/01/2021 - "Kidney function and tubular necrosis improved at 24 hours versus the untreated control group, suggesting a benefit for dual inhibition of thrombosis and inflammation by PPACK PFC NP."
3.	Inflammation (Inflammations) 11/01/2021 - "Kidney function and tubular necrosis improved at 24 hours versus the untreated control group, suggesting a benefit for dual inhibition of thrombosis and inflammation by PPACK PFC NP."
4.	Embolic Stroke 02/23/1995 - "Experimentally, hirudin, hirulog, D-Phe-L-Pro-L-Arg-CH2Cl (PPACK), and argatroban are clearly more effective than heparin in inhibiting platelet deposition and thrombus formation, and also show promise in preventing reocclusion after thrombolysis for both experimental thrombotic and embolic stroke. "
5.	Thrombocytopenia (Thrombopenia) 04/21/2000 - "In addition, unlike the other three agents, which exhibited no significant changes in hematological parameters, PPACK demonstrated dose dependent thrombocytopenia. " 12/01/1984 - "Leukopenia and thrombocytopenia were observed in the Echis and Echis + PPACK groups.(ABSTRACT TRUNCATED AT 250 WORDS)" 06/01/1986 - "Hemolysis was observed only in the Echis group, whereas thrombocytopenia and leukopenia were noted in both the Echis and the Echis + PPACK groups. "

Related Drugs and Biologics

1.	Heparin (Liquaemin)
2.	Hirudins
3.	argatroban (MPQA)
4.	Albumins
5.	bivalirudin (Angiomax)
6.	Thrombin
7.	Hemostatics (Antihemorrhagics)
8.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
9.	vorapaxar
10.	arginine chloromethyl ketone

Related Therapies and Procedures

1.	Stents
2.	Intravenous Administration
3.	Carotid Endarterectomy
4.	Therapeutics
5.	Lasers (Laser)